Target 2035 – an update on private sector contributions
Suzanne Z. Ackloo, Albert A. Antolín, José Manuel Bartolomé, Hartmut Beck, Alex N. Bullock, Ulrich A. K. Betz, Jark Böttcher, Peter J. Brown, Menorca Chaturvedi, Alisa Crisp, Danette L. Daniels, Jan Dreher, Kristina Edfeldt, A.M. Edwards, Ursula Egner, Jonathan M. Elkins, Christian Fischer, Tine Glendorf, Steven D. Goldberg, Ingo Volker Hartung · RSC Medicinal Chemistry · 2023
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.